The US FDA has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting for Tuesday, July 19, 2016.  The Committee will discuss biologics license application (BLA) 761032, for brodalumab injection, a human monoclonal antibody, submitted by Valeant Pharmaceuticals Luxembourg S.à.r.l (Valeant), proposed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

See the SAC Tracker report